Dextroamphetamine Sulfate
NDC Package 68382-943-01

11-digit billing NDC: 68382094301

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Dextroamphetamine Sulfate is extended-release capsules are indicated in:NarcolepsyAttention Deficit Disorder with HyperactivityAs an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. Marketed by Zydus Pharmaceuticals (usa) Inc., this product is identified by NDC 68382-943 and is authorized under FDA application ANDA209111.

Identification & Billing

NDC Package Code
68382-943-01
Package Description
100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE
Product Code
11-Digit Billing Format
68382094301
RxNorm Crosswalk
  • RxCUI: 884520 - dextroamphetamine sulfate 10 MG Extended Release Oral Capsule
  • RxCUI: 884532 - dextroamphetamine sulfate 15 MG Extended Release Oral Capsule
  • RxCUI: 884535 - dextroamphetamine sulfate 5 MG Extended Release Oral Capsule

Clinical Specifications

Proprietary Name
Dextroamphetamine Sulfate
Dosage Form
-
Usage Information
Dextroamphetamine sulfate extended-release capsules are indicated in:NarcolepsyAttention Deficit Disorder with HyperactivityAs an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of the hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; "on the go"; excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met.Special Diagnostic ConsiderationsSpecific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use of medical and special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presences of the required number of DSM-IV characteristics.Need for Comprehensive Treatment ProgramDextroamphetamine sulfate extended-release capsules are indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome. Stimulants are not intended for use in patients who exhibit symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the patient's symptoms.

Regulatory & Marketing

Labeler Name
Zydus Pharmaceuticals (usa) Inc.
FDA Application #
ANDA209111
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
06-28-2017
Listing Expiration
12-31-2022
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68382-943-01 identifies a specific commercial package of 100 capsule, extended release in 1 bottle of Dextroamphetamine Sulfate, labeled by Zydus Pharmaceuticals (usa) Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Zydus Pharmaceuticals (usa) Inc. on June 28, 2017. The current certification is valid through December 31, 2022.

How is this Zydus Pharmaceuticals (usa) Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68382094301. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
68382-943-01
11-Digit CMS (5-4-2)
68382-0943-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.